Menarini subsidiary Stemline Therapeutics has won FDA approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs that provid
AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs with a phase 2 win for its candidate camizestrant in a ph
Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.
Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme
In the third in his series of articles with speakers from this year’s Frontiers Health conference in Berlin, Marco Ricci speaks to corporate director of Demand Management & Digital Innovati
The latest crop of financings in the digital health category includes a sizeable $84 million round for Wellvana Health, with Genialis, ThoughtFull, and Mindset Health also